Suicide Deaths in People With Bipolar Disorder: Characteristics and Treatments at Time of Death
Bipolar Disorders · 2025
DOI: 10.1111/bdi.70061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bipolar Disorders, 2025. Verfasst von Ayal Schaffer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada. Hauptthemen laut MEDLINE: Bipolar Disorder, Suicide, Completed, Suicide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
This study aimed to compare suicide deaths in those with or without bipolar disorder (BD), taking into particular consideration the degree to which treatment at the time of death, according to toxicology data, reflects evidence‐based pharmacotherapy.
Methods
Coroner data were coded for all verified suicide deaths in the City of Toronto, Canada (1998–2020). Suicide decedents with BD ( n = 340) were compared to the non‐BD group ( n = 4948) on demographic, clinical, and suicide‐related variables. In a subsample of decedents, the presence and/or lethality of medications or substances at the time of death was identified from toxicology data and compared between groups and across time (two 11.5 year epochs). Data were analyzed using univariate analyses.
Results
Several noteworthy demographic, clinical, and suicide‐specific differences between BD and non‐BD suicide groups emerged. Antidepressants (48.9%) and benzodiazepines (46.7%) were the most commonly present medications among people with BD, at a proportion similar to the non‐BD group. There was a significant decrease in the presence of mood stabilizers across time (33.3% vs. 13.5%, p = 0.006), and lithium was present in only 5.8% of decedents with BD. Opioids (22.1%) and antipsychotics (22.1%) were the most common substances detected in lethal amounts in the BD group.
Conclusions
The findings of this study suggest that a substantial proportion of people with BD who die by suicide are not receiving first‐line treatments at the time of death. While causality cannot be established, further exploration of pharmacotherapy at the time of death would ideally link to living controls to address issues of risk and lethality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada.
- Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
- School of Social Work, University of Maryland, Baltimore, Maryland, USA.
- Academic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
- CADE Clinic and Mood-T, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, Australia.
- Department of Psychiatry, University of Oxford, Oxford, UK.
ORCID-Profile: Ayal Schaffer, Rachel Hb Mitchell
Zitieren
APA
Schaffer, A., Chan, P. P. M., Men, V. Y., Steinberg, R., Mitchell, R. H., Malhi, G., Yatham, L. N., & Sinyor, M. (2025). Suicide Deaths in People With Bipolar Disorder: Characteristics and Treatments at Time of Death. Bipolar Disorders. https://doi.org/10.1111/bdi.70061
Vancouver
Schaffer A, Chan PPM, Men VY, Steinberg R, Mitchell RH, Malhi G, et al. Suicide Deaths in People With Bipolar Disorder: Characteristics and Treatments at Time of Death. Bipolar Disorders. 2025. doi:10.1111/bdi.70061
BibTeX
@article{Schaffer2025,
author = {Schaffer, Ayal and Chan, Prudence Po Ming and Men, Vera Yu and Steinberg, Rosalie and Mitchell, Rachel Hb and Malhi, Gin and Yatham, Lakshmi N and Sinyor, Mark},
title = {Suicide Deaths in People With Bipolar Disorder: Characteristics and Treatments at Time of Death},
journal = {Bipolar Disorders},
year = {2025},
doi = {10.1111/bdi.70061}
}
EUVIMED